MEDP vs. PRAH, LH, EXEL, SYNH, IQV, ICLR, INCY, CRL, NRC, and OABI
Should you be buying Medpace stock or one of its competitors? The main competitors of Medpace include PRA Health Sciences (PRAH), Laboratory Co. of America (LH), Exelixis (EXEL), Syneos Health (SYNH), IQVIA (IQV), ICON Public (ICLR), Incyte (INCY), Charles River Laboratories International (CRL), National Research (NRC), and OmniAb (OABI).
Medpace (NASDAQ:MEDP) and PRA Health Sciences (NASDAQ:PRAH) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership.
Medpace has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, PRA Health Sciences has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Medpace has a net margin of 15.92% compared to PRA Health Sciences' net margin of 6.40%. Medpace's return on equity of 59.74% beat PRA Health Sciences' return on equity.
In the previous week, Medpace had 21 more articles in the media than PRA Health Sciences. MarketBeat recorded 21 mentions for Medpace and 0 mentions for PRA Health Sciences. Medpace's average media sentiment score of 0.78 beat PRA Health Sciences' score of 0.00 indicating that Medpace is being referred to more favorably in the media.
Medpace has higher earnings, but lower revenue than PRA Health Sciences. Medpace is trading at a lower price-to-earnings ratio than PRA Health Sciences, indicating that it is currently the more affordable of the two stocks.
PRA Health Sciences received 29 more outperform votes than Medpace when rated by MarketBeat users. However, 64.14% of users gave Medpace an outperform vote while only 56.46% of users gave PRA Health Sciences an outperform vote.
78.0% of Medpace shares are held by institutional investors. Comparatively, 93.9% of PRA Health Sciences shares are held by institutional investors. 20.3% of Medpace shares are held by insiders. Comparatively, 1.3% of PRA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Medpace presently has a consensus target price of $443.14, indicating a potential upside of 14.70%. Given Medpace's higher probable upside, equities analysts plainly believe Medpace is more favorable than PRA Health Sciences.
Summary
Medpace beats PRA Health Sciences on 13 of the 17 factors compared between the two stocks.
Get Medpace News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
